Monthly Archives: September 2011

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

AB Science SA, a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), announced today the recruitment of the first patient in the phase 3 study evaluating masitinib in severe persistent asthma. "Improving precision of … Continue reading

Posted in Uncategorized | Leave a comment

How estrogen decreases risk and delays onset and progression of Alzheimer's disease

An influential article in the journal Progress in Neurobiology provided one of the first comprehensive reviews of how estrogen potentially can protect against Alzheimer’s disease and other neurological disorders. But there also are risks. The Women’s Health Initiative found that … Continue reading

Posted in Uncategorized | Leave a comment

QIAGEN announces formation of subsidiary in India

QIAGEN today announced the formation of its India subsidiary, QIAGEN India Pvt. Ltd., and the beginning of direct sales in the country. Until now, QIAGEN products have been sold in India through distributor partnerships. The move to a deeper engagement … Continue reading

Posted in Uncategorized | Leave a comment

Targeting UROD enzyme boosts effects of radiotherapy and chemotherapy in head, neck tumors

Cancer researchers at Princess Margaret Hospital (PMH) have discovered that targeting an enzyme called Uroporphyrinogen Decarboxylase (UROD) can sensitize diseased tissue to radiation and chemotherapy, which could mean fewer side effects for individuals with head and neck cancer. The move … Continue reading

Posted in Uncategorized | Leave a comment

MGH investigators develop novel system to deliver growth factors to chronic wounds

Massachusetts General Hospital investigators have developed a novel system for delivery of growth factors to chronic wounds such as pressure sores and diabetic foot ulcers. The authors describe developing a fusion protein from recombinant KGF and elastin-like-peptides, which are major … Continue reading

Posted in Uncategorized | Leave a comment

FDA issues Complete Response letter for Avodart sNDA for reduction of prostate cancer risk

GlaxoSmithKline (GSK) today announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug Application (sNDA) for Avodart?® (dutasteride) for reducing the risk of prostate cancer in men … Continue reading

Posted in Uncategorized | Leave a comment

U.S. FDA announces link between breast implants and ALCL

The U.S. Food and Drug Administration today announced a possible association between saline and silicone gel-filled breast implants and anaplastic large cell lymphoma, a very rare type of cancer. Health care professionals are requested to report all confirmed cases of … Continue reading

Posted in Uncategorized | Leave a comment